Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 5843-5853

  Matsuo, Miki ^a   Cui, Longzhu ^a,b   Kim, Jeeyoung ^a   Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; CYTIDINE PHOSPHATE; DNA FRAGMENT; RNA POLYMERASE; VANCOMYCIN; ANTIINFECTIVE AGENT; CYTIDYLATE KINASE; DNA DIRECTED RNA POLYMERASE; NUCLEOSIDE MONOPHOSPHATE KINASE; RNA POLYMERASE BETA SUBUNIT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENOME; CELL GROWTH; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSMISSION ELECTRON MICROSCOPY; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; BACTERIAL GENE; CELL WALL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HIGH THROUGHPUT SEQUENCING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ULTRASTRUCTURE;

ANTI-BACTERIAL AGENTS; CELL WALL; DNA-DIRECTED RNA POLYMERASES; GENE EXPRESSION REGULATION, BACTERIAL; GENES, BACTERIAL; GENOME, BACTERIAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NUCLEOSIDE-PHOSPHATE KINASE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84887503315     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00425-13     Document Type: Article

References (53)

1. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
2. Hiramatsu K, Kapi M, Tajima Y, Cui L, Trakulsomboon S, Ito T. 2004. Advance in vancomycin-resistance research in Staphylococcus aureus, p 289-298. In Alekshun M, McDermott P, White D (ed), Frontiers in antibiotic resistance: a tribute to Stuart B. Levy. ASM Press, Washington, DC.
3. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
4. Cui L, Neoh HM, Shoji M, Hiramatsu K. 2009. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycinintermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 1231-1234.
5. Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K. 2008. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycinintermediate resistance to vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 52:45-53.
6. Howden BP, Stinear TP, Allen DL, Johnson PD, Ward PB. 2008. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob. Agents Chemother. 52:3755-3762.
7. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, Bell J, Coombs G, Bennett-Wood V, Porter JL, Robins-Browne R, Davies JK, Seemann T, Stinear TP. 2011. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog. 7:e1002359. doi:10.1371/journal.ppat.1002359.
8. Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, Chambers HF, Tomasz A. 2012. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300. PLoS Pathog. 8:e1002505. doi:10 .1371/journal.ppat.1002505.
9. Watanabe Y, Cui L, Katayama Y, Kishii K, Hiramatsu K. 2011. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J. Clin. Microbiol. 49:2680-2684.
10. Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K. 2011. Mutation ofRNApolymerase beta subunit (rpoB) promotes hVISAto- VISA phenotypic conversion of strain Mu3. Antimicrob. Agents Chemother. 55:4188-4195.
11. Passalacqua KD, Satola SW, Crispell EK, Read TD. 2012. A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin. Antimicrob. Agents Chemother. 56:5212-5223.
12. Matsuo M, Kurokawa K, Lee BL, Sekimizu K. 2010. Shuttle vectors derived from pN315 for study of essential genes in Staphylococcus aureus. Biol. Pharm. Bull. 33:198-203.
13. Bae T, Schneewind O. 2006. Allelic replacement in Staphylococcus aureus with inducible counter-selection. Plasmid 55:58-63.
14. Cui L, Isii T, Fukuda M, Ochiai T, Neoh HM, Camargo IL, Watanabe Y, Shoji M, Hishinuma T, Hiramatsu K. 2010. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 54:5222-5233.
15. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, CG, Kim MN, Ploy MC, El-Solh N, Ferraz V, Hiramatsu K. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14.
16. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, Richardson P, Bruce D, Rubin E, Myers E, Siggia ED, Tomasz A. 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U. S. A. 104:9451-9456.
17. Shoji M, Cui L, Iizuka R, Komoto A, Neoh HM, Watanabe Y, Hishinuma T, Hiramatsu K. 2011. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob. Agents Chemother. 55:3870-3881.
18. Finan JE, Archer GL, Pucci MJ, Climo MW. 2001. Role of penicillinbinding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:3070-3075.
19. Cosgrove SE, Carroll KC, Perl KC. 2004. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 39:539-545.
20. Gardete S, Aires-De-Sousa M, Faustino A, Ludovice AM, de Lencastre H. 2008. Identification of the first vancomycin intermediate-resistant Staphylococcus aureus (VISA) isolate from a hospital in Portugal. Microb. Drug Resist. 14:1-6.
21. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A. 2003. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin- resistant S. aureus under the impact of antibiotics administered for chemotherapy. J. Clin. Microbiol. 41:1687-1693.
22. Dhaliwal B, Ren J, Lockyer M, Charles I, Hawkins AR, Stammers DK. 2006. Structure of Staphylococcus aureus cytidine monophosphate kinase in complex with cytidine 5=-monophosphate. Acta Crystallogr. Sect. F Struct. Biol. Cryst Commun. 62:710-715.
23. Walker NJ, Clark EA, Ford DC, Bullifent HL, McAlister EV, Duffield ML, Acharya KR, Oyston PC. 2012. Structure and function of cytidine monophosphate kinase from Yersinia pseudotuberculosis, essential for virulence but not for survival. Open Biol. 2:120142.
24. Barrick D, Villanueba K, Childs J, Kalil R, Schneider TD, Lawrence CE, Gold L, Stormo GD. 1994. Quantitative analysis of ribosome binding sites in E. coli. Nucleic Acids Res. 22:1287-1295.
25. Hiramatsu K, Igarashi M, Morimoto Y, Baba T, Umekita M, Akamatsu Y. 2012. Curing bacteria of antibiotic resistance: reverse antibiotics, a novel class of antibiotics in nature. Int. J. Antimicrob. Agents 39:478-485.
26. Herbert S, Bera A, Nerz C, Kraus D, Peschel A, Goerke C, Meehl M, Cheung A, Götz F. 2007. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog. 3:e102. doi:10.1371/journal.ppat.0030102.
27. Cui L, Iwamoto A, Lian JQ, Neoh HM, Maruyama T, Horikawa Y, Hiramatsu K. 2006. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:428-438.
28. Valentini G, Chiarelli L, Fortin R, Speranza ML, Galizzi A, Mattevi A. 2000. The allosteric regulation of pyruvate kinase. J. Biol. Chem. 275: 18145-18152.
29. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276-2285.
30. Sadykov MR, Mattes TA, Luong TT, Zhu Y, Day SR, Sifri CD, Lee CY, Somerville GA. 2010. Tricarboxylic acid cycle-dependent synthesis of Staphylococcus aureus type 5 and 8 capsular polysaccharides. J. Bacteriol. 192:1459-1462.
31. Navarre WW, Schneewind O. 1999. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol. Mol. Biol. Rev. 63:174-229.
32. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K. 1998. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42:199-209.
33. Peschel A, Vuong C, Otto M, Gotz F. 2000. The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob. Agents Chemother. 44:2845-2847.
34. Atilano ML, Pereira PM, Yates J, Reed P, Veiga H, Pinho MG, Filipe SR. 2010. Teichoic acids are temporal and spatial regulators of peptidoglycan cross-linking in Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 107: 18991-18996.
35. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K. 1998. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J. Antimicrob. Chemother. 42:315-320.
36. Sieradzki K, Tomasz A. 2003. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus. J. Bacteriol. 185:7103-7110.
37. Gold L, Pribnow D, Schneider T, Shinedling S, Singer BS, Stormo G. 1981. Translational initiation in prokaryotes. Annu. Rev. Microbiol. 35: 365-403.
38. Kozak M. 2005. Regulation of translation via mRNA structure in prokaryotes and eukaryotes. Gene 361:13-37.
39. Fricke J, Neuhard J, Kelln RA, Pedersen S. 1995. The cmk gene encoding cytidine monophosphate kinase is located in the rpsA operon and is required for normal replication rate in Escherichia coli. J. Bacteriol. 177:517-523.
40. Beck CF, Neuhard J, Thomassen E, Ingraham JL, Kleker E. 1974. Salmonella typhimurium mutants defective in cytidine monophosphate kinase (cmk). J. Bacteriol. 120:1370-1379.
41. Mengin-Lecreulx D, van Heijenoort J. 1994. Copurification of glucosamine- 1-phosphate acetyltransferase and N-acetylglucosamine-1- phosphate uridyltransferase activities of Escherichia coli: characterization of the glmU gene product as a bifunctional enzyme catalyzing two subsequent steps in the pathway for UDP-N-acetylglucosamine synthesis. J. Bacteriol. 176:5788-5795.
42. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. 2002. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc. Natl. Acad. Sci. U. S. A. 99:7687-7692.
43. Huang TW, Chen FJ, Miu WC, Liao TL, Lin AC, Huang IW, Wu KM, Tsai SF, Chen YT, Lauderdale TL. 2012. Complete genome sequence of Staphylococcus aureus M013, a pvl-positive, ST59-SCCmec type V strain isolated in Taiwan. J. Bacteriol. 194:1256-1257.
44. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, O'Hara CM, McAllister SK, Clark NC, Hiramatsu K. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.
45. Sieradzki K, Roberts RB, Haber SW, Tomasz A. 1999. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340:517-523.
46. Boyle-Vavra S, Carey RB, Daum RS. 2001. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J. Antimicrob. Chemother. 48:617-625.
47. Kim MN, Pai CH, Woo JH, Ryu JS, Hiramatsu K. 2000. Vancomycinintermediate Staphylococcus aureus in Korea. J. Clin. Microbiol. 38:3879-3881.
48. Hood J, Edwards GFS, Cosgrove B, Curran E, Morrison D, Gemmell CG. 2000. Vancomycin-intermediate Staphylococcus aureus at a Scottish hospital. J. Infect. 40:A11.
49. Ploy MC, Grélaud C, Martin C, de Lumley L, Denis F. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212.
50. Chesneau O, Morvan A, Solh NE. 2000. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J. Antimicrob. Chemother. 45: 887-890.
51. Ferraz V, Dusé AG, Kassel M, Black AD, Ito T, Hiramatsu K. 2000. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S Afr. Med. J. 90:1113.
52. Oliveira GA, Dell'Aquila AM, Masiero RL, Levy CE, Gomes MS, Cui L, Hiramatsu K, Mamizuka EM. 2001. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect. Control Hosp. Epidemiol. 22:443-448.
53. Lulitanond A, Engchanil C, Chaimanee P, Vorachit M, Ito T, Hiramatsu K. 2009. The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand. J. Clin. Microbiol. 47:2311-2316.